Tuberculosis

Barr Receives Approval For Generic Myambutol Tablets

Published in TB and Outbreaks Week, December 25th, 2001

Barr Laboratories, Inc., has received approval from the U.S. Food & Drug Administration for ethambutol hydrochloride tablets 400 mg, USP, the generic equivalent of Dura Pharmaceuticals, Inc.'s Myambutol tablets. Barr's ethambutol will be the only generically available product.

"The company is pleased to add ethambutol to our portfolio of antibacterial products and plans to launch the product immediately," said Bruce L. Downey, Barr's chairman and CEO.

Myambutol is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry